- Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
- Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
- Cybin is confident this added focus will better enable the evaluation of patient outcomes
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy.
“The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.”
Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform.
Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model.
These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.
Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.